Patents Represented by Attorney, Agent or Law Firm Robert R. Cook
-
Patent number: 6462177Abstract: Disclosed are nucleic acids encoding novel proteins, designated kd312. Also disclosed are amino acid sequences for kd312 polypeptides, methods for preparing kd312 polypeptides, and other related aspects.Type: GrantFiled: March 31, 1998Date of Patent: October 8, 2002Assignee: Amgen Inc.Inventor: Kwang-Mu Yen
-
Patent number: 6143874Abstract: Disclosed are nucleic acids encoding novel neurotrophic factors, designated NNT-1. Also disclosed are amino acid sequences for NNT-1 polypeptides, methods for preparing NNT-1 polypeptides, and other related aspects. Such polypeptides are active in stimulating B-cell and/or T cell production, as well as reducing inflammatory responses.Type: GrantFiled: January 30, 1998Date of Patent: November 7, 2000Assignee: Amgen IncInventor: Ming-shi Chang
-
Patent number: 6054294Abstract: Disclosed are nucleic acids encoding novel neurotrophic factors, designated NNT-1. Also disclosed are amino acid sequences for NNT-1 polypeptides, methods for preparing NNT-1 polypeptides, and other related aspects.Type: GrantFiled: December 12, 1997Date of Patent: April 25, 2000Assignee: Amgen Inc.Inventor: Ming-shi Chang
-
Patent number: 5989538Abstract: Mpl ligand analogs having one or more changed glycosylation sites as compared to a naturally occurring mpl ligand sequence of a corresponding number of amino acids are disclosed. The invention also relates to DNA sequences encoding mpl ligand analogs, recombinant plasmids and host cells for analog expression, and therapeutic compositions including such analogs.Type: GrantFiled: September 11, 1997Date of Patent: November 23, 1999Assignee: Amgen Inc.Inventor: Steven G. Elliott
-
Patent number: 5795569Abstract: Disclosed are novel proteins, referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands or thrombopoietin, that have a biological activity of stimulating the growth of megakaryocytes and augmenting the differentiation or maturation of megakaryocytes, ultimately to result in the production of platelets. MGDF derivatives comprising MGDF molecules attached to water soluble polymers, such as polyethylene glycol, are also disclosed, along with methods for their preparation. Also disclosed are processes for obtaining the MGDFs in homogeneous form from natural sources and producing them by recombinant genetic engineering techniques from mammals, including humans.Type: GrantFiled: October 12, 1994Date of Patent: August 18, 1998Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Jakob M. Bogenberger, Robert A. Bosselman, Pamela Hunt, Olaf B. Kinstler, Babru B. Samal
-
Patent number: 5766593Abstract: The invention relates to anti-inflammatory peptides that are based on peptide regions 7-10, 11-14, and 57-64 of CD14.Type: GrantFiled: December 30, 1994Date of Patent: June 16, 1998Assignee: Amgen Inc.Inventors: Henri S. Lichenstein, Samuel D. Wright, Linda O. Narhi, Shao-Chieh Juan
-
Patent number: 5766581Abstract: Disclosed are novel proteins, referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands), that have a biological activity of stimulating the growth of megakaryocytes and augmenting the differentiation or maturation of megakaryocytes, ultimately to result in the production of platelets. MGDF derivatives comprising MGDF molecules attached to water soluble polymers, such as polyethylene glycol, are also disclosed, along with methods for their preparation. The MGDF proteins and derivatives are useful in methods for treating mammals to increase platelets and/or megakaryocytes. Also disclosed are processes for obtaining the MGDFs in homogeneous form from natural sources and producing them by recombinant genetic engineering techniques from mammals, including humans.Type: GrantFiled: March 30, 1995Date of Patent: June 16, 1998Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Jakob M. Bogenberger, Robert A. Bosselman, Pamela Hunt, Olaf B. Kinstler, Babru B. Samal
-
Patent number: 5756083Abstract: Mpl ligand analogs having one or more changed glycosylation sites as compared to a naturally occurring mpl ligand sequence of a corresponding number of amino acids are disclosed. The invention also relates to DNA sequences encoding mpl ligand analogs, recombinant plasmids and host cells for analog expression, and therapeutic compositions including such analogs.Type: GrantFiled: February 9, 1996Date of Patent: May 26, 1998Assignee: Amgen Inc.Inventor: Steven G. Elliott
-
Patent number: 5741772Abstract: Disclosed are nucleic acids encoding novel neurotrophic factors, designated NNT-1. Also disclosed are amino acid sequences for NNT-1 polypeptides, methods for preparing NNT-1 polypeptides, and other related aspects.Type: GrantFiled: February 3, 1997Date of Patent: April 21, 1998Assignee: Amgen Inc.Inventor: Ming-shi Chang
-
Patent number: 5696250Abstract: MGDF analogs having one or more changed glycosylation sites as compared to a naturally occuring MGDF sequence of a corresponding number of amino acids are disclosed. The invention also relates to DNA sequences encoding said MGDF analogs, recombinant plasmids and host cells for analog expression, and therapeutic compositions including such analogs.Type: GrantFiled: February 15, 1995Date of Patent: December 9, 1997Assignee: Amgen Inc.Inventor: Steven G. Elliott
-
Patent number: 5591718Abstract: The invention relates to a novel factor comprising a polypeptide denominated ENA-78, said factor being derived from epithelial cells and having the ability to activate neutrophils, as well as DNA coding for such factors, methods of treating neutrophil deficiencies, methods of identifying inhibitors of ENA-78 using a novel assay, the inhibitors identified by such an assay, and methods for treating acute and chronic lung disorders using such inhibitors.Type: GrantFiled: November 15, 1994Date of Patent: January 7, 1997Inventor: Alfred Walz
-
Patent number: 5498599Abstract: Disclosed is a method for increasing the number of platelets in a mammal, which comprises administering to the mammal a platelet number increasing effective amount of an unbound, preferably a soluble, MPL receptor.Type: GrantFiled: January 21, 1994Date of Patent: March 12, 1996Assignee: AMGEN Inc.Inventors: Esther S. Choi, Martha M. Hokom, Pamela Hunt, Janet L. Nichol
-
Patent number: 5405772Abstract: A serum-free or serum-depleted medium for the short- and long-term proliferation and development of cells, particularly hematopoietic cells and bone marrow stromal cells, the medium comprising cell proliferation and development effective amounts of:a standard culture medium such as Iscove's modified Dulbecco's medium; serum albumin; transferrin; a source of lipids and fatty acids; cholesterol; a reducing agent; pyruvate; a glucocorticoid (when the cells to be cultured are hematopoietic cells); nucleosides for synthesis of DNA and RNA; growth factors that stimulate the proliferation and development of stromal cells and cells from a variety of tissues or organs, such as epidermal growth factor, fibroblast growth factor, platelet derived growth factor, and insulin; and extracellular matrix materials, such as collagen, fibronectin, and laminin.Type: GrantFiled: June 18, 1993Date of Patent: April 11, 1995Assignee: Amgen Inc.Inventor: Ian L. O. Ponting
-
Patent number: 5401651Abstract: The invention relates to a novel factor comprising a polypeptide denominated ENA-78, said factor being derived from epithelial cells and having the ability to activate neutrophils, as well as DNA coding for such factors, methods of treating neutrophil deficiencies, methods of identifying inhibitors of ENA-78 using a novel assay, the inhibitors identified by such an assay, and methods for treating acute and chronic lung disorders using such inhibitors.Type: GrantFiled: October 16, 1991Date of Patent: March 28, 1995Inventor: Alfred Walz
-
Patent number: 5372808Abstract: Methods for the treatment of cell proliferation disorders, viral infections, and other conditions without causing significant side effects normally associated with interferon therapy, involving administering to a patient in need thereof a therapeutically effective amount of consensus human leukocyte interferon are disclosed. Also disclosed are pharmaceutical compositions of consensus human leukocyte interferon.Type: GrantFiled: April 15, 1992Date of Patent: December 13, 1994Assignee: Amgen Inc.Inventors: Lawrence M. Blatt, Milton W. Taylor